Asthma Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Anti- inflammatory, Bronchodilators), By Product (Inhalers, Nebulizers), By Routeof Administration (Oral, Inhaled), By Region, And Segment Forecasts, 2024 - 2030
Asthma Therapeutics Market Growth & Trends
The global asthma therapeutics market size is expected to reach USD 37.91 billion by 2030, expanding at a CAGR of 5.3% from 2024 to 2030, according to a new report by Grand View Research, Inc. The increasing prevalence of asthma coupled with the adoption of biologics as a long-term treatment option to treat the severe form of asthma is expected to offer this market with lucrative growth opportunities. According to the statistics published by the World Allergy Journal, in May 2014, patients suffering from asthma registered around 300 million and the number is expected to soar due to a large number of individuals inclining towards unhealthy dietary habits and sedentary lifestyles.
In addition, patent expiration of branded drugs, such as Singulair, Advair and other major drugs during the forecast period has led to a stiff generic competition, which will negatively impact the asthma therapeutics market growth in the coming years. On the contrary, the introduction of biologics is accruing towards the increasing market share of the asthma therapeutics segment, and is anticipated to continue during the forecast period.
The enhanced demand for personalized medicine approach as opposed to the conventional medication prescription pattern for treatment of severe asthma is anticipated to aid the emergence of asthma therapeutics market in the future. In addition, development of technologically advanced products, such as pressurized metered dose inhalers and smart inhalers, equipped with sensor technology and inbuilt wireless communication system is further expected to propel the asthma therapeutics market growth in the next seven years.
Asthma Therapeutics Market Report Highlights
- The anti-inflammatory drug class is expected to exhibit rapid growth of over the forecast period owing to the introduction of affordable and innovative biologics targeting the severe asthma condition. In addition, the awareness gained pertaining to the benefits rendered by the biologics and monoclonal antibodies is anticipated to exhibit an upward shift in the market expansion in the coming years.
- The dry powder inhalers (DPIs) are expected to be the fastest growing segment due to the increasing adoption of these devices because of their high clinical efficiency than other inhalers. They are able to deliver both, small and large-sized drug components and dispense specialty engineered molecules. These related merits have spiked the adoption rates thereby contributing towards the risen market penetration.
- Rising number of individuals opting for alternative treatment options, such as inhaled fixed-dose combination drugs for asthma medication is anticipated to serve this market with future growth opportunities.
- Some of the key players operating in the asthma therapeutics market include AstraZeneca Plc, Philips Healthcare, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline Plc, Sanofi-Aventis SA, CareFusion Corporation, Sunovion Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, Roche Diagnostics, and Merck& Co., Inc.
- Market leaders are focusing on the introduction of technologically advanced devices and novel, improved biologics to gain a competitive advantage. The asthma therapeutics segment has a very strong pipeline as there are almost 100 novel molecules that are in the development phase and manufacturers are focusing on the development of personalized medication. The aforementioned factors collectively strengthen the industry growth in the near future.
- For instance, drug molecules, such as Cinquil by Teva Pharmaceutical Industries Ltd., Lebrikizumab by Roche (Phase III), Mastinib by AB Science (Phase II/III), and Bosatria by GlaxoSmithKline Plc (Phase III), are in the development stage undergoing clinical research trials. Their commercial availability during the forecast period is expected to provide a boost to this vertical.
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Drug Class
- 1.2.2. Product
- 1.2.3. Route of Administration
- 1.2.4. Regional scope
- 1.2.5. Estimates and forecasts timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR’s internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
- 1.4.5.1. Data for Primary Interviews in North America
- 1.4.5.2. Data for Primary Interviews in Europe
- 1.4.5.3. Data for Primary Interviews in Asia Pacific
- 1.4.5.4. Data for Primary Interviews in Latin America
- 1.4.5.5. Data for Primary Interviews in MEA
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
- Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Drug class outlook
- 2.2.2. Product outlook
- 2.2.3. Rout of administration outlook
- 2.2.4. Regional outlook
- 2.3. Competitive Insights
- Chapter 3. Asthma Therapeutics Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.1.1. Increasing incidence of asthma
- 3.2.1.2. Emergence of novel biologics
- 3.2.1.3. Rising awareness programs
- 3.2.2. Market restraint analysis
- 3.2.2.1. Patent expiration of branded drugs
- 3.2.2.2. Regulatory challenges
- 3.3. Asthma Therapeutics Market Analysis Tools
- 3.3.1. Industry Analysis - Porter’s
- 3.3.1.1. Supplier power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrant
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Technological landscape
- 3.3.2.3. Economic landscape
- Chapter 4. Asthma Therapeutics Market: Drug Class Estimates & Trend Analysis
- 4.1. Drug Class Market Share, 2023 & 2030
- 4.2. Segment Dashboard
- 4.3. Global Asthma Therapeutics Market by Drug Class Outlook
- 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 4.4.1. Anti- inflammatory
- 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
- 4.4.2. Bronchodilators
- 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
- 4.4.3. Combination Therapy
- 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
- Chapter 5. Asthma Therapeutics Market: Product Estimates & Trend Analysis
- 5.1. Product Market Share, 2023 & 2030
- 5.2. Segment Dashboard
- 5.3. Global Asthma Therapeutics Market by Product Outlook
- 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 5.4.1. Inhalers
- 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
- 5.4.1.2. Dry Powder
- 5.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
- 5.4.1.3. Metered Dose
- 5.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
- 5.4.1.4. Soft Mist
- 5.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
- 5.4.2. Nebulizers
- 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
- Chapter 6. Asthma Therapeutics Market: Route of Administration Estimates & Trend Analysis
- 6.1. Route of Administration Market Share, 2023 & 2030
- 6.2. Segment Dashboard
- 6.3. Global Asthma Therapeutics Market by Route of Administration Outlook
- 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 6.4.1. Oral
- 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
- 6.4.2. Inhaled
- 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
- 6.4.3. Others
- 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
- Chapter 7. Asthma Therapeutics Market: Regional Estimates & Trend Analysis
- 7.1. Regional Market Share Analysis, 2023 & 2030
- 7.2. Regional Market Dashboard
- 7.3. Global Regional Market Snapshot
- 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
- 7.5. North America
- 7.5.1. U.S.
- 7.5.1.1. Key country dynamics
- 7.5.1.2. Regulatory framework/ reimbursement structure
- 7.5.1.3. Competitive scenario
- 7.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Billion)
- 7.5.2. Canada
- 7.5.2.1. Key country dynamics
- 7.5.2.2. Regulatory framework/ reimbursement structure
- 7.5.2.3. Competitive scenario
- 7.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Billion)
- 7.6. Europe
- 7.6.1. Germany
- 7.6.1.1. Key country dynamics
- 7.6.1.2. Regulatory framework/ reimbursement structure
- 7.6.1.3. Competitive scenario
- 7.6.1.4. Germany market estimates and forecasts 2018 to 2030 (USD Billion)
- 7.6.2. UK
- 7.6.2.1. Key country dynamics
- 7.6.2.2. Regulatory framework/ reimbursement structure
- 7.6.2.3. Competitive scenario
- 7.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Billion)
- 7.6.3. France
- 7.6.3.1. Key country dynamics
- 7.6.3.2. Regulatory framework/ reimbursement structure
- 7.6.3.3. Competitive scenario
- 7.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Billion)
- 7.6.4. Italy
- 7.6.4.1. Key country dynamics
- 7.6.4.2. Regulatory framework/ reimbursement structure
- 7.6.4.3. Competitive scenario
- 7.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Billion)
- 7.6.5. Spain
- 7.6.5.1. Key country dynamics
- 7.6.5.2. Regulatory framework/ reimbursement structure
- 7.6.5.3. Competitive scenario
- 7.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Billion)
- 7.6.6. Norway
- 7.6.6.1. Key country dynamics
- 7.6.6.2. Regulatory framework/ reimbursement structure
- 7.6.6.3. Competitive scenario
- 7.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Billion)
- 7.6.7. Sweden
- 7.6.7.1. Key country dynamics
- 7.6.7.2. Regulatory framework/ reimbursement structure
- 7.6.7.3. Competitive scenario
- 7.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Billion)
- 7.6.8. Denmark
- 7.6.8.1. Key country dynamics
- 7.6.8.2. Regulatory framework/ reimbursement structure
- 7.6.8.3. Competitive scenario
- 7.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Billion)
- 7.7. Asia Pacific
- 7.7.1. Japan
- 7.7.1.1. Key country dynamics
- 7.7.1.2. Regulatory framework/ reimbursement structure
- 7.7.1.3. Competitive scenario
- 7.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Billion)
- 7.7.2. China
- 7.7.2.1. Key country dynamics
- 7.7.2.2. Regulatory framework/ reimbursement structure
- 7.7.2.3. Competitive scenario
- 7.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Billion)
- 7.7.3. India
- 7.7.3.1. Key country dynamics
- 7.7.3.2. Regulatory framework/ reimbursement structure
- 7.7.3.3. Competitive scenario
- 7.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Billion)
- 7.7.4. South Korea
- 7.7.4.1. Key country dynamics
- 7.7.4.2. Regulatory framework/ reimbursement structure
- 7.7.4.3. Competitive scenario
- 7.7.4.4. South Korea market estimates and forecasts 2018 to 2030 (USD Billion)
- 7.7.5. Australia
- 7.7.5.1. Key country dynamics
- 7.7.5.2. Regulatory framework/ reimbursement structure
- 7.7.5.3. Competitive scenario
- 7.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Billion)
- 7.7.6. Thailand
- 7.7.6.1. Key country dynamics
- 7.7.6.2. Regulatory framework/ reimbursement structure
- 7.7.6.3. Competitive scenario
- 7.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Billion)
- 7.8. Latin America
- 7.8.1. Brazil
- 7.8.1.1. Key country dynamics
- 7.8.1.2. Regulatory framework/ reimbursement structure
- 7.8.1.3. Competitive scenario
- 7.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Billion)
- 7.8.2. Mexico
- 7.8.2.1. Key country dynamics
- 7.8.2.2. Regulatory framework/ reimbursement structure
- 7.8.2.3. Competitive scenario
- 7.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Billion)
- 7.8.3. Argentina
- 7.8.3.1. Key country dynamics
- 7.8.3.2. Regulatory framework/ reimbursement structure
- 7.8.3.3. Competitive scenario
- 7.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Billion)
- 7.9. MEA
- 7.9.1. South Africa
- 7.9.1.1. Key country dynamics
- 7.9.1.2. Regulatory framework/ reimbursement structure
- 7.9.1.3. Competitive scenario
- 7.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Billion)
- 7.9.2. Saudi Arabia
- 7.9.2.1. Key country dynamics
- 7.9.2.2. Regulatory framework/ reimbursement structure
- 7.9.2.3. Competitive scenario
- 7.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Billion)
- 7.9.3. UAE
- 7.9.3.1. Key country dynamics
- 7.9.3.2. Regulatory framework/ reimbursement structure
- 7.9.3.3. Competitive scenario
- 7.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Billion)
- 7.9.4. Kuwait
- 7.9.4.1. Key country dynamics
- 7.9.4.2. Regulatory framework/ reimbursement structure
- 7.9.4.3. Competitive scenario
- 7.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Billion)
- Chapter 8. Competitive Landscape
- 8.1. Recent Developments & Impact Analysis, By Key Market Participants
- 8.2. Company/Competition Categorization
- 8.3. Vendor Landscape
- 8.3.1. List of key distributors and channel partners
- 8.3.2. Key customers
- 8.3.3. Key company market share analysis, 2023
- 8.3.4. Teva Pharmaceutical Industries Ltd
- 8.3.4.1. Company overview
- 8.3.4.2. Financial performance
- 8.3.4.3. Product benchmarking
- 8.3.4.4. Strategic initiatives
- 8.3.5. GSK plc
- 8.3.5.1. Company overview
- 8.3.5.2. Financial performance
- 8.3.5.3. Product benchmarking
- 8.3.5.4. Strategic initiatives
- 8.3.6. Merck & Co., Inc.
- 8.3.6.1. Company overview
- 8.3.6.2. Financial performance
- 8.3.6.3. Product benchmarking
- 8.3.6.4. Strategic initiatives
- 8.3.7. F. Hoffmann-La Roche Ltd
- 8.3.7.1. Company overview
- 8.3.7.2. Financial performance
- 8.3.7.3. Product benchmarking
- 8.3.7.4. Strategic initiatives
- 8.3.8. AstraZeneca
- 8.3.8.1. Company overview
- 8.3.8.2. Financial performance
- 8.3.8.3. Product benchmarking
- 8.3.8.4. Strategic initiatives
- 8.3.9. Boehringer Ingelheim International GmbH
- 8.3.9.1. Company overview
- 8.3.9.2. Financial performance
- 8.3.9.3. Product benchmarking
- 8.3.9.4. Strategic initiatives
- 8.3.10. Sanofi
- 8.3.10.1. Company overview
- 8.3.10.2. Financial performance
- 8.3.10.3. Product benchmarking
- 8.3.10.4. Strategic initiatives
- 8.3.11. Koninklijke Philips N.V.
- 8.3.11.1. Company overview
- 8.3.11.2. Financial performance
- 8.3.11.3. Product benchmarking
- 8.3.11.4. Strategic initiatives
- 8.3.12. BD
- 8.3.12.1. Company overview
- 8.3.12.2. Financial performance
- 8.3.12.3. Product benchmarking
- 8.3.12.4. Strategic initiatives
- 8.3.13. Covis Pharma
- 8.3.13.1. Company overview
- 8.3.13.2. Financial performance
- 8.3.13.3. Product benchmarking
- 8.3.13.4. Strategic initiatives
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook